Suramin Reconstitution Calculator

No for most off-label peptide-biohacker use cases; yes as an old antiparasitic drug for early-stage human African trypanosomiasis caused by Trypanosoma brucei rhodesiense. The corpus explicitly states this is the only human disease for which suramin is currently approved.

Suramin is a broad polyanionic drug with strong anti-purinergic activity, especially antagonism of P2 receptor signaling, but it is not selective and binds many extracellular and intracellular targets. Reported targets in the corpus include purinergic receptors, cGAS, PI3K p85α, IP5K, viral polymerases, viral nucleocapsid proteins, growth factor systems, and mitochondrial transport proteins, which explains why its effects are wide-ranging but hard to predict cleanly in vivo.

Human and animal literature in this corpus mainly uses intravenous administration for systemic exposure, and the compound’s high negative charge limits oral bioavailability and membrane permeability. In practice, oral use is not an established route for systemic suramin exposure, while injectable use is the standard research/clinical route; community protocols therefore favor IV rather than oral or subcutaneous administration for systemic effects (practitioner consensus).

The most clinically relevant low-dose human signal in this corpus is the SAT-1 autism pilot, which used low-dose suramin in children and reported safety/activity signals (RCT). Preclinical systemic dosing is much higher and route-specific: 100 mg/kg IV in a Parkinsonian rat model given on days 11 and 18, 60 mg/kg intraperitoneally twice weekly in a mouse ADPKD model, and 250 mg/kg once in a mouse neurotoxicity model that produced locomotor/sensory deficits. These numbers are not interchangeable across species or goals (animal).

A long time. Suramin is historically known for prolonged persistence, and the review literature in this corpus emphasizes its unusual pharmacology and polypharmacology. Long persistence is one reason community protocols space infusions widely rather than dose daily (practitioner consensus), and it is also why delayed toxicities matter clinically.

The most important concerns are peripheral neurotoxicity, kidney injury/phospholipidosis, and limited tissue penetration to some compartments such as brain. In preclinical work, a single 250 mg/kg dose produced sensory-motor deficits and a predominantly sensory axonal-demyelinating neuropathy phenotype, while in a Pkd1-deficient mouse model suramin reduced cyst growth but also caused tubular epithelial vacuolation consistent with phospholipidosis and worsened plasma cystatin C/NGAL despite anti-inflammatory effects. Review data also note poor oral bioavailability and limited brain penetration.

Potentially yes. Although suramin showed renoprotective or anti-inflammatory effects in some kidney injury models, the ADPKD study found tubular injury signals and phospholipidosis despite improvement in cystic pathology. For practical use, baseline and follow-up renal monitoring is reasonable if repeated systemic dosing is used (practitioner consensus).

Yes, that is a real signal rather than a theoretical risk. Preclinical work demonstrated suramin-induced peripheral sensory-motor neuropathy and calcium dysregulation in dorsal root ganglion neurons, with partial protection from nimodipine in vitro. Historical human use has also been associated with peripheral neurotoxicity according to the review summarized in the corpus.

Poorly. The review literature states that suramin’s size and high negative charge limit brain penetration. That matters because CNS effects seen in animal models may reflect peripheral immunomodulation or high-dose exposure rather than efficient BBB penetration.

Mechanistically yes, clinically unproven in this corpus. It inhibits early entry steps for several viruses and can also inhibit internal viral targets such as polymerases or nucleocapsid-RNA interactions in cell-based or structural studies. For SARS-CoV-2, suramin inhibited replication in cell culture with an EC50 around 20 μM and acted on early replication-cycle steps, possibly binding/entry. Similar target engagement is reported for orthobunyavirus and Borna virus polymerases.

Suramin is broad and dirty; selective antagonists are cleaner if you know the receptor subtype you want. The corpus shows modern selective P2X7 programs are being developed because receptor-specific inhibition can reduce inflammation with fewer off-target effects than pan-purinergic blockade. Suramin remains useful as a probe or broad antagonist, but not as a precision tool.

There is no pregnancy-safety dataset in this corpus sufficient to support routine use, and suramin has systemic multi-target effects with long persistence. Practical answer: avoid elective use during pregnancy or conception attempts unless there is a compelling medical reason and specialist oversight (practitioner consensus).

No storage guidance appears in this corpus. Practical handling depends on formulation and compounding source; injectable preparations are typically handled as clinic-administered products rather than casual self-travel items (community protocol). Because dosing is usually intermittent and often infusion-based, most users arrange administration rather than carrying multidose supplies (community protocol).